**Article**

**Evaluation of a new survivin ELISA and UBC® Rapid for the detection of bladder cancer in urine**

Jan Gleichenhagen¹, Christian Arndt², Swaantje Casjens¹, Carmen Meinig¹, Holger Gerullis³, Irina Raiko¹, Thomas Brüning¹, Thorsten Ecke⁴ and Georg Johnen¹

**Supplementary Materials**

**Supplementary Figure S1.** Comparison of different survivin assays. Obtained OD values from two commercial assays (R&D, ENZO) and the new ELISA (IPA) are plotted as signal to noise ratio (S/N) and interpolated by four-parameter logistic curve fitting.

**Supplementary Figure S2.** Comparison of values for low-grade and high-grade tumors. (a) Survivin and (b) UBC® Rapid.
Supplementary Figure S3. Scatterplot of UBC® Rapid versus survivin. The plot shows marker concentrations of the (a) tumor group \( r_s = 0.38 \) and (b) clinical control group \( r_s = 0.19 \). CI = 95% confidence interval.

Supplementary Figure S4. Venn diagram of high-grade tumors. Detected (left) and undetected (right) tumor cases by UBC® Rapid (cut-off 10 mg/l) and survivin (cut-off 0.033 ng/ml).

Supplementary Figure S5. ROC analyses of high-grade tumors and clinical controls for survivin (AUC = 0.88), UBC® Rapid (AUC = 0.88), and the combination (AUC = 0.91).